AKR1C3 Binds β‐Trcp to Promote the Degradation of TFRC to Protect Hepatocellular Carcinoma From Ferroptosis
Cancer Science · 2026
DOI: 10.1111/cas.70403 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Lei Qi und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Ferroptosis, Carcinoma, Hepatocellular, Liver Neoplasms, Aldo-Keto Reductase Family 1 Member C3. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Guizhou Provincial Science and Technology Department, State Key Laboratory of Neurology and Oncology Drug Development.
Abstract (Originalsprache)
Ferroptosis, an iron‐dependent form of programmed cell death driven by lipid peroxidation, represents a new potential therapeutic target in cancer. However, emerging evidence indicates that hepatocellular carcinoma (HCC) frequently exhibits resistance to ferroptosis induction, while the underlying molecular mechanism is poorly understood. Here, we found that aldo‐keto reductase family 1 member C3 (AKR1C3), a protein highly expressed in ferroptosis‐resistant HCC cells, negatively regulates ferroptosis in an enzyme‐independent manner. Mechanistically, AKR1C3 promotes ubiquitin‐proteasomal degradation of the transferrin receptor (TFRC), which is indispensable for cellular iron uptake. AKR1C3 knockdown restores TFRC expression, increases the level of labile iron pool, and sensitizes HCC cells to ferroptosis. Furthermore, AKR1C3 acts as a scaffolding protein to promote the degradation of TFRC and reduce iron uptake by promoting nuclear export of Beta‐transducin repeats‐containing proteins (β‐TrCP) and its binding to TFRC. Notably, AKR1C3 is upregulated in NRF2‐driven sorafenib‐resistant HCC, and its inhibition reversed ferroptosis and sorafenib resistance. Our work uncovers AKR1C3 suppresses ferroptosis in HCC by promoting β‐TrCP‐mediated TFRC degradation, positioning AKR1C3 as a promising therapeutic target to enhance ferroptosis‐based anticancer strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China.
- The State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University (Guizhou International Science & Technology Cooperation Base for Druggability Re…
- The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
- Public Experimental Platform, China Pharmaceutical University, Nanjing, Jiangsu, China.
- Department of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China.
ORCID-Profile: Li Zhao
Förderung
- National Natural Science Foundation of China
- Guizhou Provincial Science and Technology Department
- State Key Laboratory of Neurology and Oncology Drug Development
Zitieren
APA
Qi, L., Hua, J., Pan, D., Yang, W., Tian, G., Ye, F., Liu, L., Mao, Y., Guo, Q., Sun, H., & Zhao, L. (2026). AKR1C3 Binds β‐Trcp to Promote the Degradation of TFRC to Protect Hepatocellular Carcinoma From Ferroptosis. Cancer Science. https://doi.org/10.1111/cas.70403
Vancouver
Qi L, Hua J, Pan D, Yang W, Tian G, Ye F, et al. AKR1C3 Binds β‐Trcp to Promote the Degradation of TFRC to Protect Hepatocellular Carcinoma From Ferroptosis. Cancer Science. 2026. doi:10.1111/cas.70403
BibTeX
@article{Qi2026,
author = {Qi, Lei and Hua, Jingyi and Pan, Di and Yang, Wanwan and Tian, Geng and Ye, Fangyu and Liu, Lingxiang and Mao, Yuhan and Guo, Qinglong and Sun, Haopeng and Zhao, Li},
title = {AKR1C3 Binds β‐Trcp to Promote the Degradation of TFRC to Protect Hepatocellular Carcinoma From Ferroptosis},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70403}
}
EUVIMED